Connect with us


Generex Biotechnology Corp’s (OTCMKTS:GNBT) NuGenerex Immuno-Oncology Responds To FDA Regarding Its Paediatric-Focused COVID-19 Vaccine



Generex  Biotechnology Corp’s (OTCMKTS:GNBT) subsidiary NuGenerex Immuno-Oncology has announced the submission of a response to the FDA’s comments on a Pre-IND Written Response.

NuGenerex Immuno-Oncology responds to FDA’s comments Ii-Key vaccine

The response package offers important information requested by the FDA, including Li-Key epitope sequences, picked based on the ex-vivo blood screening program. It also includes the transgenic mouse immunogenicity study results showing vaccine-specific antibody production and GMP manufacturing information for Ii-Key-SARS-CoV-2 epitopes in the vaccine. There is also a revised protocol incorporating FDA’s requests and comments.

The company has previously reported ex-vivo blood screening program results, which enabled the selection of Ii-Key-SARS-CoV-2 epitopes from membrane and spike proteins based upon T-cell activation profiles. Notably, the company tested the five Ii-Key epitopes in a mouse model engineered with a human immune system part.

NuGenerx Immuno-Oncology CEO Joe Moscato said that the company has made considerable progress in Ii-Key SARS-CoV-2 vaccines. He said that a year a goo chose to use the Ii-Key tech to offer a targeted, safe, and specific Complete Vaccine™  that creates neutralizing antibodies and T-Cell activation for enhanced immune memory.

NuGenerex creating COVID-19 vaccine for pediatric and pregnant women

Generex Biotechnology and NuGenerex Immuno-Oncology have announced a partnership with Last Chance for Children’s Mission to help save the lives of children across the globe. With the COVID-19 pandemic, the company’s efforts are on helping eradicate the virus by vaccinating children in need. The pandemic has disrupted children’s lives, and so far, there is no approved vaccine for children under 12 or pregnant women.

As a result, NuGenerex’s Ii-Key COVID-19 vaccine could be vital in protecting against the virus. The Ii-Key vaccine is based on amino acid sequences mimicking the COVID-19 spike and membrane proteins. It selectively regulates immune responses targeting the SARS-CoV-2 virus without genetic material like most vaccines that use DNA and RNA vectors.

NuGenerex is focusing on creating a safe and effective COVID-19 vaccine for pregnant women and pediatric populations, populations with significant unmet needs in the race for the COVID-19 vaccine.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.


Business3 days ago

THC Biomed Intl Ltd (OTCMKTS: THCBF) Amends its Health Canada Licence to Include Three Strata Units at its Acland Road Location

Post Views: 5 It took only a year for THC Biomed Intl Ltd (OTCMKTS: THCBF) to obtain a rare license...

Business3 days ago

Tetra Bio-Pharma Inc. (OTCMKTS: TBPMF) Obtains an Approval of the Proposed Protocol Modifications to Accelerate the REBORN Study

Post Views: 37 Clinical trials are an essential component of any drug discovery and development program. Innovative research initiatives are...

Business3 days ago

The Appointment of Philip Goldberg, Formerly of Green Leaf Medical, to the Board of Directors of Columbia Care Inc. (OTCMKTS: CCHWF)

Post Views: 6 The growing acceptance and recognition of marijuana for its medical purposes has made an impact on cannabis...

Business3 days ago

Surna Inc, (OTCMKTS: SRNA) Expands its Line of Curated HVACD Family Products with the Introduction of EnviroPro™ Air Handler

Post Views: 6 The cultivation of cannabis comes with a myriad of challenges. Designing cultivation facilities and deploying the systems...

Business3 days ago

Mydecine Innovations Group Inc. (OTCMKTS: MYCOF) Supports the Launch of Version 2.0, a Digital Health Platform by its Subsidiary Mindleap Health

Post Views: 3 The COVID 19 pandemic took the world by storm and has left hundreds of thousands of people...


HempMeds Latin American Operations, a subsidiary of Medical Marijuana, Inc. (OTCMKTS: MJNA), Announces a 12% Revenue Increase in June 2021 Compared to June 2020

Post Views: 18 What comes to mind when you hear the words, “Medical marijuana?” It is seemingly regarded as the...